BioCentury | Feb 26, 2020
Product Development

Subgroup analyses help Vanda hold steady despite Phase III itch miss

...Vanda shares Wednesday mostly shrugged off a sharp decline in after-hours trading Tuesday after tradipitant missed...
...dermatitis patients, tradipitant reduced WI-NRS scores by 4.74 points vs. 3.14 for placebo (p=0.0152). Additionally, tradipitant...
...in April. Targets NK1R (TACR1) - Neurokinin 1 receptor Sandi Wong, Assistant Editor serlopitant (VPD-737, mk-0594) tradipitant (ly686017, vly-686) Vanda...
BioCentury | Feb 26, 2020
Product Development

Feb. 25 Quick Takes: Vanda’s Phase III miss; plus Iovance; 1st-twoXAR; app for AFib, stroke; ICER-Aetion; new-look Purple Book, and more

...misses in atopic dermatitis Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares tumbled after market close Tuesday after tradipitant...
...differences in baseline atopic dermatitis severity -- measured by Investigator Global Assessment (IGA) score -- tradipitant...
...VEGF - Vascular endothelial growth factor Sandi Wong, Assistant Editor, and Paul Bonanos, Associate Editor tradipitant (ly686017, vly-686) Eylea...
BioCentury | Aug 2, 2019
Company News

Aug. 1 Company Quick Takes: Nektar gains on breakthrough for NKTR-214; plus Adaptive's MRD test, Acadia, Vanda and more

...upgraded the company to buy, citing the “immediate and significant upside” for motion sickness candidate tradipitant...
BioCentury | Feb 8, 2019
Company News

Vanda sues FDA over 'unnecessary' dog testing requirement

...against FDA requesting a federal court lift a partial clinical hold the agency placed on tradipitant...
...signals for humans. Last year, tradipitant met the primary endpoint in the four-week Phase II VLY-686-2301...
...on Feb. 6. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), Washington, D.C. Business: Dermatology, gastrointestinal, neurology Chris Lieu tradipitant (ly686017, vly-686) Vanda...
BioCentury | Feb 6, 2019
Clinical News

Vanda sues FDA over 'unnecessary' dog testing requirement

...against FDA requesting a federal court lift a partial clinical hold the agency placed on tradipitant...
...signals for humans. Last year, tradipitant met the primary endpoint in the four-week Phase II VLY-686-2301...
..."Chips for Tox" ). Vanda shares fell $5 (20%) to $20.06 on Wednesday. Chris Lieu tradipitant (ly686017, vly-686) Vanda...
BioCentury | Dec 14, 2018
Clinical News

Vanda's tradipitant meets in Phase II for gastroparesis

...Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) said tradipitant met the primary endpoint in the Phase II VLY-686-2301 trial...
...receive placebo or twice-daily 85 mg oral tradipitant for four weeks. On the primary endpoint, tradipitant...
...by patient daily diaries at week four Status: Phase II data Milestone: NA Alicia Parker tradipitant (ly686017, vly-686) Eli...
BioCentury | Sep 22, 2017
Clinical News

Vanda reports mixed Phase II data from atopic dermatitis trial of tradipitant

...chronic pruritus patients with mild to severe atopic dermatitis showing that twice-daily 85 mg oral tradipitant...
...itch visual analog scale (VAS) score vs. placebo (reductions of 41.5 vs. 35.8 points, p=0.306). Tradipitant...
...NASDAQ:VNDA), Washington, D.C. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Tradipitant (formerly LY686017 , VLY-686...
BioCentury | Jul 13, 2017
Targets & Mechanisms

Insider signaling

...’s Akynzeo netupitant/palonosetron, and Opko Health Inc. ’s Varubi , oral rolapitant. In addition, Lilly’s tradipitant...
BioCentury | Mar 16, 2015
Clinical News

Tradipitant: Phase II data

...Top-line data from the double-blind, German Phase II VP-VLY-686-2101 trial in 69 atopic dermatitis patients with...
...trial in 69 atopic dermatitis patients with chronic pruritus showed that once-daily 100 mg oral tradipitant...
...NASDAQ:VNDA), Washington, D.C. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Tradipitant (formerly LY686017 , VLY-686...
BioCentury | Apr 23, 2012
Finance

Highlights of weekly biotech stock moves

...Inc. (NASDAQ:VNDA) was off $0.09 to $4.40 last week after receiving exclusive, worldwide rights to VLY-686...
...include chemotherapy-induced nausea and vomiting, postoperative nausea and vomiting, alcohol dependence, anxiety, depression and pruritus. VLY-686...
Items per page:
1 - 10 of 12